Intellia Therapeutics, Inc. (NTLA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q3 '24: 45M Q4 '24: 57.9M Q1 '25: 45.6M Q2 '25: 52.9M Q3 '25: 57.5M Q4 '25: 67.7M Q1 '26: 66.1M Q2 '26: 59.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 15M 30M 45M Q2 '19: 36.8M Q3 '19: 40M Q4 '19: 43.1M Q2 '19 Q3 '19 Q4 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '24: -537.7M Q4 '24: -534.3M Q1 '25: -541.1M Q2 '25: -512M Q3 '25: -478.7M Q4 '25: -441M Q1 '26: -420.7M Q2 '26: -423.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '24: -522.3M Q4 '24: -519M Q1 '25: -525.9M Q2 '25: -480.2M Q3 '25: -445.8M Q4 '25: -412.7M Q1 '26: -394.6M Q2 '26: -400M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q2 '19 Q3 '19 Q4 '19

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '24: -356.7M Q4 '24: -348.9M Q1 '25: -377.1M Q2 '25: -418.6M Q3 '25: -410.6M Q4 '25: -394.7M Q1 '26: -363.2M Q2 '26: -346.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '24: -363.1M Q4 '24: -354.7M Q1 '25: -381.2M Q2 '25: -421.8M Q3 '25: -412.6M Q4 '25: -395.9M Q1 '26: -363.6M Q2 '26: -348.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '24: 95.5M Q2 '24: 97M Q3 '24: 101M Q1 '25: 103.5M Q2 '25: 103.7M Q3 '25: 110.2M Q1 '26: 118.5M Q2 '26: 133.5M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '24: -5.44 Q4 '24: -5.24 Q1 '25: -5.22 Q2 '25: -4.68 Q3 '25: -4.26 Q4 '25: -3.82 Q1 '26: -3.53 Q2 '26: -3.35 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.